Beta Drugs LtdQ3 FY24Pharmaceuticals & Biotechnology

Beta Drugs Ltd

Q3 FY24 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Revenue guidance

Category 2

→Overall company growth targeted at 25% to 30% annually for the coming years.
→Export business expected to grow around 50% annually over the next 3-4 years, with focus on gaining registrations and entering EU and US markets.
→Domestic cytotoxic market expected to grow at a CAGR of 15-20%, reaching about INR 4,000-5,000 crores by 2028-2030.
→CDMO business to show steady growth with increasing sales in the second half of FY25; current first half sales around INR 72.7 crores.
→Derma segment to double revenue next financial year, reaching INR 26-30 crores with new product launches and expanded prescriber network.
→Intermediate production facility will boost internal API margins by 10-15%.
→R&D focused on launching 20-25 products and developing new NDDS and biosimilar molecules over the next 2-3 years.

Category 3

→Beta Drugs expects total company growth at 25%-30% over the next few years, with exports growing even faster.
→Export business is projected to grow around 50% annually for the next 3-4 years, aided by new registrations and dossier filings.
→API business is a key focus with plans for DMF filings and entry into regulated markets; currently exports in API are negligible but expected to grow.
→CDMO business sales showed 2%-5% growth H1 FY25, with expectations of steady and better sales in the next half.
→Derma segment aims to double sales to around INR26-30 crores next financial year with product launches and new prescriber additions.
→EBITDA margins expected to be around 22%-26% depending on segment; export margin is around 23%-26%.
→Intermediate plant investment (~INR15-20 crores) to boost margins by 10%-15%.
→Fundraise (~INR117 crores) targeted at R&D, intermediate facility, and recombinant proteins to drive future earnings growth.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Beta Drugs Ltd and 1,400+ other companies.

Yes

→Beta Drugs Limited has recently completed a fundraising of INR117 crores from marquee investors, including HealthQuad, Tanas Capital, and a generational capital fund.
→The funds raised are primarily earmarked for future growth initiatives: state-of-the-art R&D facilities (formulation and API), establishment of an intermediate plant, and venturing into recombinant proteins.
→There was no indication of any additional current or future fundraising through debt or equity during this conference call.
→The company is focusing on using internal accruals for regular capex around INR10-12 crores in FY26.
→No new fundraising beyond the mentioned INR117 crores was discussed.

→The transcript does not explicitly mention the current or expected order book or pending orders for Beta Drugs Limited.
→However, management indicates a strong pipeline with plans to launch 5 new molecules and NDDS by next year.
→The company is experiencing significant growth in exports with a 141% increase, supported by new registrations and dossier filings.
→CDMO business growth is steady with all CDMO partners retained and expected sales to improve in the second half.
→Intermediate manufacturing facility investment of INR15-20 crores aims to boost internal API production, potentially increasing margins by 10-15%.
→Expanding regulatory capabilities and approvals (EU-GMP, COFEPRIS, ZAZIBONA) indicate a growing ability to secure international contracts/orders.
→Overall, while exact order book numbers are not stated, the company projects strong demand and growth across multiple verticals driven by regulatory registrations and new product launches.

Yes

→Planned capex for FY26 excluding new projects: INR 10-12 crores from internal accruals.
→Fundraise of INR 117 crores for strategic investments:
→ - Establishing a state-of-the-art combined R&D facility (formulation + API) with INR 10-15 crores capex.
→ - Setting up an intermediate plant with an investment of INR 15-20 crores to reduce dependence on China and support API production.
→ - Future venture into recombinant proteins and biosimilars.
→R&D expense expected to rise from current 2-3% to 4-5% post new facility.
→Expansion in intermediate production aims to boost margins by 10-15% and cater initially to internal API requirements.
→Plans for EU-GMP and Mexico COFEPRIS audits to enable regulated market entry.

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Beta Drugs Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Beta Drugs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.